Anticholinergic Equivalence in Psychotropic Medications
- 20 August 2025
- journal article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 45 (6) , 609-612
Abstract
Background: Anticholinergic side effects from psychotropic medications are common and can lead to significant adverse events, including cognitive impairment and falls, particularly in vulnerable populations like the elderly. The cumulative anticholinergic burden from multiple medications is a critical concern associated with poorer clinical outcomes. Quantifying this burden is essential for safer prescribing. Methods: This article developed an anticholinergic equivalence (AE) table for various psychotropic medications. Diphenhydramine (AE=1) was used as the reference standard. AE values for other drugs were derived from their M1 muscarinic receptor binding affinities (Ki) relative to diphenhydramine. This allows estimation of the diphenhydramine equivalent burden per milligram of a given medication. Antihistaminic properties were also reviewed. Results: An AE table was generated, detailing the anticholinergic potency of numerous psychotropic agents. Values varied significantly, with older tricyclic antidepressants (eg, amitriptyline AE: 8.99) and some antipsychotics (eg, clozapine AE: 6.67, olanzapine AE: 3.08) showing high anticholinergic equivalence. Many sedating medications (eg, quetiapine, mirtazapine) are noted to have potent antihistaminic but low anticholinergic properties, clarifying that sedation is not always due to anticholinergic effects. Conclusions: The anticholinergic equivalence table provides a practical, pharmacologically based tool for psychiatrists to quantify and compare the anticholinergic potential of psychotropic medications. This can aid in minimizing cumulative anticholinergic burden, making more informed prescribing decisions, and ultimately enhancing patient safety and therapeutic outcomes, especially in high-risk groups.Keywords
This publication has 21 references indexed in Scilit:
- Cumulative Use of Strong Anticholinergics and Incident DementiaJAMA Internal Medicine, 2015
- Review of the histamine system and the clinical effects of H1 antagonists: Basis for a new model for understanding the effects of insomnia medicationsSleep Medicine Reviews, 2013
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older PersonsArchives of internal medicine (1960), 2008
- Synthesis and biodistribution of [11C]R107474, a new radiolabeled α2-adrenoceptor antagonistBioorganic & Medicinal Chemistry, 2006
- Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetineBiological Psychiatry, 2001
- 3‘-Chloro-3α-(diphenylmethoxy)tropane But Not 4‘-Chloro-3α- (diphenylmethoxy)tropane Produces a Cocaine-like Behavioral ProfileJournal of Medicinal Chemistry, 1997
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology, 1996
- Binding of antidepressants to human brain receptors: focus on newer generation compoundsPsychopharmacology, 1994
- Buspirone: review of its pharmacology and current perspectives on its mechanism of actionThe American Journal of Medicine, 1986